[Lambert-Eatone myastenic syndrome]

Area of Science:

• Neurology
• Immunology
• Clinical Medicine

Background:

• Lambert-Eatone myasthenic syndrome (LEMS) and generalized myasthenia are distinct neuromuscular junction disorders.
• Differentiating these conditions is crucial for accurate diagnosis and treatment.
• Paraneoplastic processes can be associated with LEMS, but clinical presentation may overlap.

Purpose of the Study:

• To conduct a comparative analysis of neurologic symptoms in LEMS and generalized myasthenia patients.
• To identify distinct clinical patterns that facilitate the diagnosis and differentiation of LEMS.
• To investigate the role of electrophysiological findings and autoantibodies in LEMS.

Main Methods:

• Comparative analysis of neurologic symptoms in 45 LEMS patients and 42 generalized myasthenia patients.
• Electromyography (EMG) including 40-Hz stimulation and assessment of compound muscle action potential (CMAP) amplitude.
• Serum analysis for IgG antibodies targeting P/Q type voltage-gated calcium channels.

Main Results:

• No significant clinical differences were observed between LEMS patients with or without paraneoplastic processes.
• EMG revealed reduced CMAP amplitude and incremental response at 40-Hz stimulation in LEMS.
• CMAP amplitude tripled after 20 seconds of maximal voluntary contraction in LEMS patients.
• IgG antibodies against P/Q type calcium channels were found in 89% of LEMS patients.
• Antibody-mediated inhibition of calcium influx correlated with reduced resting CMAP amplitude.

Conclusions:

• Distinct clinical and electrophysiological patterns aid in diagnosing and differentiating LEMS from generalized myasthenia.
• P/Q type calcium channel antibodies are a key biomarker for LEMS.
• The degree of calcium channel blockade by autoantibodies correlates with disease severity.